{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009166","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.240505+00:00","generated_at":"2026-06-17T21:42:45.569314+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tyra Biosciences reports 2022 net loss of $55.3M; cash $251.2M; TYRA-300 in clinic for oncology and achondroplasia","bullets":["Q4 2022 net loss $12.9M vs $9.9M in Q4 2021; full year net loss $55.3M vs $26.3M.","Cash and equivalents $251.2M as of Dec 31, 2022; provides >2 years runway.","Initiated patient dosing with TYRA-300 in Phase 1/2 SURF301 oncology study in Nov 2022.","Expanded TYRA-300 development into achondroplasia; IND planned for Phase 2 in 2024.","FDA cleared IND for TYRA-200 Phase 1 study in FGFR-resistant cholangiocarcinoma; first patient expected 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009166","json":"https://secwatch.observer/filing/0000950170-23-009166.json","markdown":"https://secwatch.observer/filing/0000950170-23-009166.md","text":"https://secwatch.observer/filing/0000950170-23-009166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017023009166/0000950170-23-009166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017023009166/tyra-20230322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:42:45.569314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"386a45c7791caf2d4c3b1be77589e831f4941fc0","claim":"Tyra Biosciences, Inc. reported financial results for the quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On March 22, 2023, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017023009166/0000950170-23-009166-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}